Lake Street Advisors Group LLC Makes New $236,000 Investment in DaVita Inc. (NYSE:DVA)

Lake Street Advisors Group LLC acquired a new stake in shares of DaVita Inc. (NYSE:DVA) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 1,437 shares of the company’s stock, valued at approximately $236,000.

A number of other institutional investors have also made changes to their positions in the stock. Wedmont Private Capital grew its holdings in DaVita by 4.4% during the third quarter. Wedmont Private Capital now owns 1,776 shares of the company’s stock valued at $280,000 after purchasing an additional 75 shares during the last quarter. Blue Trust Inc. raised its holdings in DaVita by 58.6% in the 2nd quarter. Blue Trust Inc. now owns 211 shares of the company’s stock worth $29,000 after acquiring an additional 78 shares during the period. First Trust Direct Indexing L.P. lifted its position in DaVita by 3.9% during the 1st quarter. First Trust Direct Indexing L.P. now owns 2,590 shares of the company’s stock worth $358,000 after acquiring an additional 98 shares during the last quarter. Quent Capital LLC boosted its holdings in DaVita by 21.0% during the first quarter. Quent Capital LLC now owns 581 shares of the company’s stock valued at $80,000 after acquiring an additional 101 shares during the period. Finally, FinTrust Capital Advisors LLC increased its stake in shares of DaVita by 17.6% in the first quarter. FinTrust Capital Advisors LLC now owns 837 shares of the company’s stock worth $116,000 after purchasing an additional 125 shares during the period. 90.12% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other news, insider Kathleen Alyce Waters sold 7,857 shares of the business’s stock in a transaction that occurred on Tuesday, August 13th. The stock was sold at an average price of $146.21, for a total value of $1,148,771.97. Following the transaction, the insider now directly owns 83,011 shares of the company’s stock, valued at $12,137,038.31. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, insider Kathleen Alyce Waters sold 7,857 shares of the company’s stock in a transaction that occurred on Tuesday, August 13th. The shares were sold at an average price of $146.21, for a total transaction of $1,148,771.97. Following the transaction, the insider now directly owns 83,011 shares in the company, valued at approximately $12,137,038.31. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Javier Rodriguez sold 32,176 shares of the business’s stock in a transaction that occurred on Monday, August 26th. The stock was sold at an average price of $155.93, for a total transaction of $5,017,203.68. Following the completion of the transaction, the chief executive officer now owns 905,659 shares of the company’s stock, valued at $141,219,407.87. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 173,482 shares of company stock valued at $27,387,069. 2.00% of the stock is currently owned by insiders.

DaVita Stock Performance

NYSE:DVA opened at $156.99 on Monday. The company has a quick ratio of 1.12, a current ratio of 1.16 and a debt-to-equity ratio of 9.94. The firm has a 50-day moving average price of $158.09 and a 200 day moving average price of $145.67. The firm has a market capitalization of $13.77 billion, a PE ratio of 17.84, a price-to-earnings-growth ratio of 0.93 and a beta of 0.87. DaVita Inc. has a 12-month low of $75.47 and a 12-month high of $168.50.

DaVita (NYSE:DVA) last issued its quarterly earnings data on Tuesday, August 6th. The company reported $2.59 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.47 by $0.12. DaVita had a return on equity of 77.00% and a net margin of 6.86%. The company had revenue of $3.19 billion during the quarter, compared to analysts’ expectations of $3.15 billion. During the same period last year, the business earned $2.08 earnings per share. The business’s revenue was up 6.2% on a year-over-year basis. Research analysts anticipate that DaVita Inc. will post 9.99 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of analysts have issued reports on the company. Truist Financial raised their target price on DaVita from $165.00 to $175.00 and gave the company a “hold” rating in a report on Monday, October 7th. UBS Group boosted their price objective on shares of DaVita from $169.00 to $175.00 and gave the stock a “buy” rating in a report on Thursday, August 8th. Bank of America boosted their price target on DaVita from $139.00 to $145.00 and gave the company an “underperform” rating in a research note on Wednesday, August 7th. Finally, TD Cowen raised their price objective on DaVita from $139.00 to $150.00 and gave the stock a “hold” rating in a research report on Wednesday, July 24th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and two have assigned a buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $159.00.

DaVita Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.